Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Newsom-Davis

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Annals of Translational Medicine|December 7, 2019
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancerRossana Berardi, Matteo Santoni, Silvia Rinaldi, et al.
Oncotarget|November 19, 2016
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapyRossana Berardi, Matteo Santoni, Thomas Newsom-Davis, et al.
Oncotarget|March 31, 2016
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapyRossana Berardi, Silvia Rinaldi, Matteo Santoni, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 1, 2019
Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor TherapyDavid J Pinato, Heather Urus, Thomas Newsom-Davis, et al.
British Journal of Cancer|May 11, 2021
COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentaryThomas Round, Veline L'Esperance, Joanne Bayly, et al.
BMJ Open|December 10, 2023
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilotChloe Beard, Chris A Rogers, Leah Fleming, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancerAndrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, et al.
JAMA Oncology|September 13, 2019
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With CancerDavid J Pinato, Sarah Howlett, Diego Ottaviani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel Neal, Nick Pavlakis, Sang-We Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Annals of Translational Medicine|December 7, 2019
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancerRossana Berardi, Matteo Santoni, Silvia Rinaldi, et al.
Oncotarget|November 19, 2016
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapyRossana Berardi, Matteo Santoni, Thomas Newsom-Davis, et al.
Oncotarget|March 31, 2016
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapyRossana Berardi, Silvia Rinaldi, Matteo Santoni, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 1, 2019
Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor TherapyDavid J Pinato, Heather Urus, Thomas Newsom-Davis, et al.
British Journal of Cancer|May 11, 2021
COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentaryThomas Round, Veline L'Esperance, Joanne Bayly, et al.
BMJ Open|December 10, 2023
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilotChloe Beard, Chris A Rogers, Leah Fleming, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancerAndrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, et al.
JAMA Oncology|September 13, 2019
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With CancerDavid J Pinato, Sarah Howlett, Diego Ottaviani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel Neal, Nick Pavlakis, Sang-We Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
Pageof 4